Back to resultsAn Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Primary Purpose
Rheumatoid Arthritis
Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LY3871801
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis
Eligibility Criteria
Inclusion Criteria: Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria. Have moderately-to-severely active RA at screening and baseline, defined by the presence of ≥6 swollen joints based on 66 joint count, and ≥6 tender joints based on 68 joint count. Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 1 conventional synthetic disease modifying anti rheumatic drug (csDMARD) and either 1 biologic (bDMARD), or targeted synthetic (tsDMARD) treatment. Exclusion Criteria: Have Class IV RA according to ACR revised criteria Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to poorly controlled diabetes or hypertension chronic kidney disease stage IIIa or IIIb, IV, or V symptomatic heart failure according to New York Heart Association class II, III, or IV myocardial infarction,unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before randomization severe chronic pulmonary disease, for example, requiring oxygen therapy major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to systemic lupus erythematosus psoriatic arthritis axial spondyloarthritis,including ankylosing spondylitis and non-radiographic axial spondyloarthritis reactive arthritis gout scleroderma polymyositis dermatomyositis active fibromyalgia, or multiple sclerosis
Sites / Locations
- Integrity Clinical ResearchRecruiting
- Advanced Clinical Research of Orlando - OcoeeRecruiting
- Conquest ResearchRecruiting
- PMG Research of SalisburyRecruiting
- Medicina ReumatológicaRecruiting
- Instituto de Alta Complejidad San IsidroRecruiting
- Mautalen Salud e InvestigaciónRecruiting
- CENUDIABRecruiting
- Medical PlusRecruiting
- CHU de NiceRecruiting
- CHU Strasbourg-HautepierreRecruiting
- Centre Hospitalier Universitaire de Reims - l'Hôpital Maison BlancheRecruiting
- Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire CarémeauRecruiting
- CHU Montpellier Lapeyronie HospitalRecruiting
- Infirmerie Protestante de LyonRecruiting
- CHD VendeeRecruiting
- Centre Hospitalier Regional D'OrleansRecruiting
- Hopitaux Universitaires Paris Centre-Hopital Cochin
- University Hospital of Cologne
- Rheumazentrum Ratingen StudienambulanzRecruiting
- Institut für Präventive Medizin & Klinische Forschung GbRRecruiting
- HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg GmbHRecruiting
- Avron HospitalsRecruiting
- Sushruta Multispeciality Hospital & Research CentreRecruiting
- Government Medical College And Hospital - NagpurRecruiting
- All India Institute of Medical Sciences (AIIMS) - NagpurRecruiting
- Grant Medical Foundation - Ruby Hall Clinic
- CIMAB SA de CV
- Biológicos Especializados
- Cicmex Centro de Investigación Clínica de México
- Medical Care and Research SA de CV
- Kohler and Milstein Research S.A. de C.V.
- Investigacion y Biomedicina de Chihuahua
- Estudios Clínicos Internacionales (ECI) - Querétaro
- Centro de Atención e Investigación Cardiovascular del Potosí
- The Dudley Group NHS Foundation Trust
- Northumbria Healthcare NHS Foundation Trust
- New Cross Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Placebo Comparator
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
LY3871801 Phase 2a
Placebo Phase 2a
LY3871801 Dose 1 Phase 2b
LY3871801 Dose 2 Phase 2b
LY3871801 Dose 3 Phase 2b
Placebo Phase 2b
Arm Description
Participants will receive LY3871801 administered orally.
Participants will receive placebo.
Participants will receive LY3871801 administered orally.
Participants will receive LY3871801 administered orally.
Participants will receive LY3871801 administered orally.
Participants will receive placebo.
Outcomes
Primary Outcome Measures
Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)
Phase 2b: Percentage of Participants Achieving American College of Rheumatology (ACR)50
Secondary Outcome Measures
Phase 2a: Percentage of Participants Achieving ACR20/50/70
Phase 2b: Change from Baseline in DAS28-hsCRP
Phase 2b: Percentage of Participants Achieving ACR20/70
Change from Baseline in Simplified Disease Activity Index (SDAI)
Change from Baseline in Clinical Disease Activity Index (CDAI)
Change from Baseline in ACR Core Set Values 68 Tender Joint Counts
Change from Baseline in ACR Core Set Values 66 Swollen Joint Counts
Change from Baseline in ACR Core Set Values Physician's Global Assessment of Disease Activity (PhGADA) Visual Analog Scale (VAS)
Change from Baseline in ACR Core Set Values Patient's Global Assessment of Disease Activity (PaGADA) VAS
Change from Baseline for Participant's Assessment of Arthritis Pain (VAS)
Change from Baseline for Participant's Assessment of Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI)
Change from Baseline the Duration and Severity of Morning Joint Stiffness
Change from Baseline for Short Form-36 (SF-36) Physical Component Summary Score
Change from Baseline for SF-36 Mental Component Summary Score
Pharmacokinetics (PK) Trough Plasma Concentrations of LY3871801
Full Information
NCT ID
NCT05848258
First Posted
April 28, 2023
Last Updated
October 18, 2023
Sponsor
Eli Lilly and Company
Collaborators
Rigel Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT05848258
Brief Title
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Official Title
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Study Type
Interventional
2. Study Status
Record Verification Date
October 1, 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 23, 2023 (Actual)
Primary Completion Date
June 3, 2024 (Anticipated)
Study Completion Date
July 15, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company
Collaborators
Rigel Pharmaceuticals
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
380 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
LY3871801 Phase 2a
Arm Type
Experimental
Arm Description
Participants will receive LY3871801 administered orally.
Arm Title
Placebo Phase 2a
Arm Type
Placebo Comparator
Arm Description
Participants will receive placebo.
Arm Title
LY3871801 Dose 1 Phase 2b
Arm Type
Experimental
Arm Description
Participants will receive LY3871801 administered orally.
Arm Title
LY3871801 Dose 2 Phase 2b
Arm Type
Experimental
Arm Description
Participants will receive LY3871801 administered orally.
Arm Title
LY3871801 Dose 3 Phase 2b
Arm Type
Experimental
Arm Description
Participants will receive LY3871801 administered orally.
Arm Title
Placebo Phase 2b
Arm Type
Placebo Comparator
Arm Description
Participants will receive placebo.
Intervention Type
Drug
Intervention Name(s)
LY3871801
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered orally
Primary Outcome Measure Information:
Title
Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)
Time Frame
Baseline, Week 12
Title
Phase 2b: Percentage of Participants Achieving American College of Rheumatology (ACR)50
Time Frame
Baseline to Week 12
Secondary Outcome Measure Information:
Title
Phase 2a: Percentage of Participants Achieving ACR20/50/70
Time Frame
Baseline to Week 12
Title
Phase 2b: Change from Baseline in DAS28-hsCRP
Time Frame
Baseline, Week 12
Title
Phase 2b: Percentage of Participants Achieving ACR20/70
Time Frame
Week 12
Title
Change from Baseline in Simplified Disease Activity Index (SDAI)
Time Frame
Baseline, Week 12
Title
Change from Baseline in Clinical Disease Activity Index (CDAI)
Time Frame
Baseline, Week 12
Title
Change from Baseline in ACR Core Set Values 68 Tender Joint Counts
Time Frame
Baseline, Week 12
Title
Change from Baseline in ACR Core Set Values 66 Swollen Joint Counts
Time Frame
Baseline, Week 12
Title
Change from Baseline in ACR Core Set Values Physician's Global Assessment of Disease Activity (PhGADA) Visual Analog Scale (VAS)
Time Frame
Baseline, Week 12
Title
Change from Baseline in ACR Core Set Values Patient's Global Assessment of Disease Activity (PaGADA) VAS
Time Frame
Baseline, Week 12
Title
Change from Baseline for Participant's Assessment of Arthritis Pain (VAS)
Time Frame
Baseline, Week 12
Title
Change from Baseline for Participant's Assessment of Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time Frame
Baseline, Week 12
Title
Change from Baseline the Duration and Severity of Morning Joint Stiffness
Time Frame
Baseline, Week 12
Title
Change from Baseline for Short Form-36 (SF-36) Physical Component Summary Score
Time Frame
Baseline, Week 12
Title
Change from Baseline for SF-36 Mental Component Summary Score
Time Frame
Baseline, Week 12
Title
Pharmacokinetics (PK) Trough Plasma Concentrations of LY3871801
Time Frame
Baseline through Week 20
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria.
Have moderately-to-severely active RA at screening and baseline, defined by the presence of
≥6 swollen joints based on 66 joint count, and
≥6 tender joints based on 68 joint count.
Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 1 conventional synthetic disease modifying anti rheumatic drug (csDMARD) and either 1 biologic (bDMARD), or targeted synthetic (tsDMARD) treatment.
Exclusion Criteria:
Have Class IV RA according to ACR revised criteria
Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to
poorly controlled diabetes or hypertension
chronic kidney disease stage IIIa or IIIb, IV, or V
symptomatic heart failure according to New York Heart Association class II, III, or IV
myocardial infarction,unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before randomization
severe chronic pulmonary disease, for example, requiring oxygen therapy
major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to
systemic lupus erythematosus
psoriatic arthritis
axial spondyloarthritis,including ankylosing spondylitis and non-radiographic axial spondyloarthritis
reactive arthritis
gout
scleroderma
polymyositis
dermatomyositis
active fibromyalgia, or
multiple sclerosis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone
1-317-615-4559
Email
ClinicalTrials.gov@lilly.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Integrity Clinical Research
City
Doral
State/Province
Florida
ZIP/Postal Code
33122
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
305-552-7660
First Name & Middle Initial & Last Name & Degree
Adolfo A. Cueli
Facility Name
Advanced Clinical Research of Orlando - Ocoee
City
Ocoee
State/Province
Florida
ZIP/Postal Code
34761
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariangeli Arroyo
Facility Name
Conquest Research
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
407-916-0060
First Name & Middle Initial & Last Name & Degree
Anand Patel
Facility Name
PMG Research of Salisbury
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rakesh C Patel
Facility Name
Medicina Reumatológica
City
San Fernando
State/Province
Buenos Aires
ZIP/Postal Code
1646
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Alejandra Cusa
Facility Name
Instituto de Alta Complejidad San Isidro
City
San Isidro
State/Province
Buenos Aires
ZIP/Postal Code
1642
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
Phone
5491164620494
First Name & Middle Initial & Last Name & Degree
Maria Alicia Lazaro
Facility Name
Mautalen Salud e Investigación
City
Buenos Aires
State/Province
Ciudad Autónoma De Buenos Aires
ZIP/Postal Code
C1128AAF
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julio Hofman
Facility Name
CENUDIAB
City
Ciudad Autónoma de Buenos Aire
ZIP/Postal Code
C1440AAD
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
Phone
1146820269
First Name & Middle Initial & Last Name & Degree
Norma Beatriz Verzero
Facility Name
Medical Plus
City
Uherske Hradiste
State/Province
Zlínský Kraj
ZIP/Postal Code
686 01
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Dokoupilova
Facility Name
CHU de Nice
City
Nice
State/Province
Alpes-Maritimes
ZIP/Postal Code
06000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian ROUX
Facility Name
CHU Strasbourg-Hautepierre
City
Strasbourg
State/Province
Alsace
ZIP/Postal Code
67098
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
0388127953
First Name & Middle Initial & Last Name & Degree
Jacques-Eric GOTTENBERG
Facility Name
Centre Hospitalier Universitaire de Reims - l'Hôpital Maison Blanche
City
Reims
State/Province
Champagne-Ardenne
ZIP/Postal Code
51092
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Hugues SALMON
Facility Name
Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau
City
Nîmes
State/Province
Gard
ZIP/Postal Code
30029
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cécile Gaujoux-Viala
Facility Name
CHU Montpellier Lapeyronie Hospital
City
Montpellier
State/Province
Hérault
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacques Morel
Facility Name
Infirmerie Protestante de Lyon
City
Caluire et Cuire
State/Province
Rhône
ZIP/Postal Code
69300
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
0472007152
First Name & Middle Initial & Last Name & Degree
André BASCH
Facility Name
CHD Vendee
City
La Roche-sur-Yon
State/Province
Vendée
ZIP/Postal Code
85000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stéphane Varin
Facility Name
Centre Hospitalier Regional D'Orleans
City
Orléans
ZIP/Postal Code
45067
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33238744014
First Name & Middle Initial & Last Name & Degree
Carine SALLIOT
Facility Name
Hopitaux Universitaires Paris Centre-Hopital Cochin
City
Paris
ZIP/Postal Code
75679
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jérôme Avouac
Facility Name
University Hospital of Cologne
City
Köln
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
50937
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
004922147842882
First Name & Middle Initial & Last Name & Degree
David Kofler
Facility Name
Rheumazentrum Ratingen Studienambulanz
City
Ratingen
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
40878
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
4921025533788
First Name & Middle Initial & Last Name & Degree
Siegfried Wassenberg
Facility Name
Institut für Präventive Medizin & Klinische Forschung GbR
City
Magdeburg
State/Province
Sachsen-Anhalt
ZIP/Postal Code
39110
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
00493917273904
First Name & Middle Initial & Last Name & Degree
Rüdiger Klaus Möricke
Facility Name
HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg GmbH
City
Hamburg
ZIP/Postal Code
20095
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Everding
Facility Name
Avron Hospitals
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380013
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vishnu Devkinandan Sharma
Facility Name
Sushruta Multispeciality Hospital & Research Centre
City
Hubli
State/Province
Karnataka
ZIP/Postal Code
580021
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr.VIKRAM Haridas
Facility Name
Government Medical College And Hospital - Nagpur
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
440009
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chandrashekar Madhukarrao Atkar
Facility Name
All India Institute of Medical Sciences (AIIMS) - Nagpur
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
441108
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rajashree Sanjay Khot
Facility Name
Grant Medical Foundation - Ruby Hall Clinic
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411001
Country
India
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
02066455495
First Name & Middle Initial & Last Name & Degree
Ajit Nalawade
Facility Name
CIMAB SA de CV
City
Torreon
State/Province
Coahuila
ZIP/Postal Code
27000
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
8711921259
First Name & Middle Initial & Last Name & Degree
SANDRA ARACELI SICSIK AYALA
Facility Name
Biológicos Especializados
City
Mexico City
State/Province
Distrito Federal
ZIP/Postal Code
06700
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francisco G Medina
Facility Name
Cicmex Centro de Investigación Clínica de México
City
Morelia
State/Province
Michoacán
ZIP/Postal Code
58020
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ma. Dolores Alonso -Martinez
Facility Name
Medical Care and Research SA de CV
City
Merida
State/Province
Yucatán
ZIP/Postal Code
97070
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
9999203879
First Name & Middle Initial & Last Name & Degree
Aaron Alejandro Barrera Rodríguez
Facility Name
Kohler and Milstein Research S.A. de C.V.
City
Mérida
State/Province
Yucatán
ZIP/Postal Code
97070
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jesus Abraham Simon Campos
Facility Name
Investigacion y Biomedicina de Chihuahua
City
Chihuahua
ZIP/Postal Code
31000
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
526144373003
First Name & Middle Initial & Last Name & Degree
Cesar Francisco Pacheco-Tena
Facility Name
Estudios Clínicos Internacionales (ECI) - Querétaro
City
Querétaro
ZIP/Postal Code
76000
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roman Cardona
Facility Name
Centro de Atención e Investigación Cardiovascular del Potosí
City
San Luis Potosí
ZIP/Postal Code
78200
Country
Mexico
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
524448340596
First Name & Middle Initial & Last Name & Degree
Victor Manuel Dimas-Pecina
Facility Name
The Dudley Group NHS Foundation Trust
City
Dudley
State/Province
England
ZIP/Postal Code
DY1 2HQ
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
01384244754
First Name & Middle Initial & Last Name & Degree
Karen Douglas
Facility Name
Northumbria Healthcare NHS Foundation Trust
City
Newcastle upon Tyne
State/Province
North Tyneside
ZIP/Postal Code
NE29 8NH
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
07881610598
First Name & Middle Initial & Last Name & Degree
Ismael Atchia
Facility Name
New Cross Hospital
City
Wolverhampton
ZIP/Postal Code
WV10 0QP
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sabrina Raizada
12. IPD Sharing Statement
Links:
URL
https://trials.lilly.com/en-US/trial/401857
Description
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Learn more about this trial
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
We'll reach out to this number within 24 hrs